Examples of possible biology-based therapeutic options available for treatment of basal-like breast cancer include anti-EGFR monoclonal antibodies (cetuximab and panitumumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib and lapatinib), imatinib for c-Kit kinase inhibition and bevacizumab for VEGF inhibition [106,107,108,109,110]. Here, EGFR is linked to breast cancer.